ArticleFrontiers in immunology2025
A shikonin-based hydrogel dressing exhibiting synergistic anti-inflammatory, anti-angiogenic, and anti-fibrotic effects for the prevention of hypertrophic scars.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Current therapeutic strategies and available research models for investigating hypertrophic scars.Frontiers in pharmacology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: The management and prevention of hypertrophic scars present significant challenges in clinical medicine. The development of hypertrophic scars primarily results from angiogenesis, localized inflammatory responses, and the excessive deposition of collagen during the wound healing process. Given the practical requirements for clinical applications, the development of a multifunctional dressing that exhibits synergistic effects and adapts to wounds of diverse shapes is of paramount importance. Hydrogels have emerged as promising biomaterials in dermatological applications due to their excellent biocompatibility, injectability, and strong adhesion. Shikonin (SHI), a compound derived from traditional Chinese medicine, exhibits anti-inflammatory and antioxidant properties that facilitate wound healing. It is posited that SHI possesses diverse pharmacological potential for the prevention and treatment of scars. Methods: Based on these characteristics, this study developed a methacrylated gelatin (GelMA) dressing incorporated with shikonin. In vitro experiments were conducted to evaluate the material properties and biocompatibility of SHI-GelMA. Concurrently, an in vivo rabbit ear model was established to assess the efficacy of SHI-GelMA in inhibiting scar hyperplasia through treatment and subsequent observation. Results: By utilizing GelMA's superior biological properties, the dressing enhances the therapeutic efficacy of SHI on hypertrophic scars while addressing challenges related to drug release kinetics. In vitro experiments demonstrated that the SHI-GelMA dressing exhibits favorable biocompatibility. Importantly, both in vitro and in vivo studies consistently indicated that SHI-GelMA synergistically prevents and inhibits hypertrophic scar formation through SHI's principal anti-inflammatory, anti-angiogenic, and anti-fibrotic mechanisms. Discussion: In summary, we have successfully developed a functional wound dressing that incorporates the diverse bioactivities of SHI, offering novel materials and strategies for the synergistic prevention and treatment of hypertrophic scars.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.